Diseases [C] » Eye Diseases [C11] » Retinal Diseases » Retinal Degeneration » Macular Degeneration » Macular Edema
Description
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90) MeSH
Hierarchy View
Approved Indicated Drugs (5)
Phase 4 Indicated Drugs (25)
Phase 2 Indicated Drugs (49)
Other Experimental Indicated Drugs (18)
Organization Involved with Phase 4 Indications (119)
Asociación para Evitar la Ceguera en México
Association for Innovation and Biomedical Research on Light and Image (AIBILI)
Center For Excellence In Eye Care
Charlotte Eye Ear Nose and Throat Assciates, PA
Ciusss de L'Est de l'Île de Montréal
Federal University of Sao Paulo
Gottfried Wilhelm Leibniz Universität Hannover
Icahn School of Medicine at Mount Sinai
King Khaled Eye Specialist Hospital
National University of Singapore
Nune Eye Hospital, Seoul, Korea
Ophthalmic Consultants of the Capital Region
Oregon Health and Science University
Postgraduate Institute of Medical Education and Research
Retina Macula Specialists of Miami, LLC
Retina-Vitreous Associates Medical Group
Retina Vitreous Associates of Florida
Southeast Clinical Research Associates, LLC
Organization Involved with Phase 3 Indications (66)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Beijing Bethune public welfare fund
Chengdu Kanghong Biotech Co.,Ltd.
Chinese Academy of Medical Sciences
European Society of Cataract and Refractive Surgeons
Isfahan Ophthalmology Research Center
Jaeb Center for Health Research
National Institutes of Health (NIH)
Second Military Medical University
Shahid Beheshti University of Medical Sciences
Organization Involved with Phase 2 Indications (110)
Adelaide Eye and Retina Centre
Al-Farabi Kazakh National University
Black Hills Regional Eye Institute
Case Western Reserve University
Centre for Eye Research Australia (CERA)
Chinese University of Hong Kong
Cumberland Valley Retina Consultants, PC
Especialistas en Retina Medica y Quirurgica Grupo de Investigacion
Federal University of Pernambuco
Instituto Mexicano de Oftalmologia
J. Arch McNamara Research Fund
KalVista Pharmaceuticals, Ltd.
Long Island Vitreoretinal Consultants
Mid-Atlantic Retina Consultations, Inc.
National Autonomous University of Mexico
National Health and Medical Research Council, Australia
Oncology Service, Wills Eye Institute
People's Liberation Army of China
Retina Associates of Florida, P.A.
Retinal Consultants of Arizona
Rocky Mountain Retina Consultants
Sanwa Kagaku Kenkyusho Co., Ltd.
Sydney Eye Hospital/Save Sight Institution
Sydney Retina Clinic & Day Surgery
Texas Retina Associates in Arlington
Texas Retina Associates in Dallas
Universidad Autonoma de Queretaro
Universidad Nacional Autonoma de Mexico
University of British Columbia
University of Southern California
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (22)
Fountain Medical Development Co., Ltd.
Illinois Retina and Eye Associates
Ophthalmic Consultants of Boston
Retina Vitreous Associates Beverley Hills, California
Organization Involved with Other Experimental Indications (45)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
